Mankind Pharma is involved in the R&D, manufacture, and distribution of a wide variety of pharmaceutical formulations for both acute and chronic therapeutic areas, in addition to a number of consumer healthcare items. According to the draft red herring prospectus (DRHP), Mankind Pharma will open for public subscription with a total amount of the initial public offering (IPO) of ₹4,326.36 Crores, or 40,058,844 equity shares with a face value of ₹1. The price range per share for this offering is from ₹1026 to ₹1080. 13 Shares constitute the minimum order quantity. Opening day for the Mankind Pharma IPO is April 25, 2023, while the last day is April 27, 2023. The IPO’s registrar is Kfin Technologies Limited. It is planned that the stock be listed on the BSE and the NSE. The issue is being led by a team consisting of Kotak Mahindra Capital Company, Axis Capital, IIFL Securities, Jefferies India, and JP Morgan India.
About Mankind Pharma
Mankind Pharma Limited was founded in 1991, and since then it has researched, developed, manufactured, and marketed a wide range of pharmaceutical formulations for both acute and chronic conditions. The company operates in the anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins/minerals/nutrients, and respiratory domains in India.
When it comes to the Indian pharmaceutical business, Mankind Pharma has one of the largest networks of medical representatives. As of the end of the Financial Year 2022, their formulations were prescribed by over 80% of Indian doctors. The company has been honored with a number of accolades, such as the 2022 Silver Medal from the National Awards for Manufacturing Competitiveness Assessment presented by the International Research Institute of Manufacturing and the 2022 Best of Bharat Awards presented by exchange4media.
The Company had approximately 600 scientists working for it as of December 31, 2022, and its own in-house R&D center had four locations in IMT Manesar, Gurugram, Haryana, and Thane, Maharashtra.
Mankind Pharma IPO Issue Details
| Issue Type | Book Built IPO Issue |
| Issue Opens | 25th April 2023 |
| Issue Closes | 27th April 2023 |
| Face Value | Rs 1 Per Share |
| Issue Price | Rs 1026 to Rs 1080 Per Share |
| Issue Size | 40,058,844 Shares (Rs 4326.36 crores) |
| Minimum Order Quantity | 13 Shares |
| Listing | NSE, BSE |
Purpose of the Issue
All of the Offer Proceeds will go to the Selling Shareholders in direct proportion to the number of Offered Shares sold by each Selling Shareholder in the Offer.
Mankind Pharma Limited — Company Contact Details
- Registered Office: Office No. 208, Okhla Industrial Estate, Phase-III, New Delhi 110020
- Corporate Office: Office No. 262, Okhla Industrial Estate, Phase-III, New Delhi 110020
- Telephone: +91-11 4684 6700
- Website:https://www.mankindpharma.com/
Mankind Pharma Limited IPO – Lead Managers of the Issue
- The lead Manager to this IPO issue are:-
- Kotak Mahindra Capital Company Limited
- Axis Capital Limited
- IIFL Securities Ltd
- Jefferies India Private Limited
- J.P. Morgan India Private Limited
Mankind Pharma Limited IPO – Registrar of the Issue
The registrar of this IPO issue is Kfin Technologies Limited.
Mankind Pharma Limited IPO Issue Prospectus
Click here to read the Final Prospectus of this IPO Issue.
Disclaimer: Investingly just provides basic information as update about the issues. Investingly never gives advices or recommendations to anyone. Investments into securities are subject to market risk. Please read the offer and issue documents carefully before investing. It is also advised to consult your financial advisor of necessary suggestions.
